Neurometabolic and Genetic Disorders
Swanbio Therapeutics Limited focuses on adrenomyeloneuropathy, a rare genetic disorder affecting the nervous system and spinal cord, with clinical interest centered on disease-modifying treatment for adults living with this condition.
- Adrenomyeloneuropathy
- ABCD1-related disease
- Rare inherited neurologic disease
The sponsor’s research activity is directed toward therapeutic approaches that address the underlying neurologic and metabolic consequences of this inherited condition.
Gene Therapy
The company is active in gene therapy for a severe inherited neurologic disease, with emphasis on restoring function linked to the defective ABCD1 gene.
- AAV9-based gene delivery
- Intrathecal administration
- Genetic correction strategies
This area reflects a therapeutic interest in targeted molecular intervention for central nervous system involvement in rare disease.
Neurology and Spinal Cord Disease
Research activity is concentrated in neurology, particularly disorders with spinal cord and motor pathway involvement, where clinical need remains substantial in adult patients.
- Motor dysfunction
- Myelopathy
- Adult neurologic impairment
The sponsor’s clinical interest includes conditions that affect mobility, strength, and long-term neurologic function.
Rare Disease Therapeutics
Swanbio Therapeutics Limited is involved in the development of treatments for rare diseases, with a specific focus on an orphan neurologic indication that requires specialized clinical evaluation.
- Orphan disease development
- Adult rare disease care
- Targeted molecular therapy
The sponsored program is aligned with therapeutic innovation in a narrowly defined orphan neurology setting.
